Griseofulvin
(Fulvicin P/G, Fulvicin U/F, Gris-Peg, Grisactin) |
Category:
Description:
Indications:
-
Fungal
infections of the skin, hair, and nails caused by susceptible
organisms.
-
Antifungal
spectrum usually includes: Trichophyton
rubrum, T. tonsurans, T. mentagropytes, T. interdigitalis, T.
verrucosum, T. megninii, T. gallinae, T. crateriform, T. sulphureum,
T. schoenleinii, Microsporum audouinii, M. canis, M. gypseum,
Epidermophyton floccosum
Contraindications:
-
Porphyria
-
Hepatocellular
failure
Precautions:
Adverse
Reactions (Side Effects):
-
CNS:
dizziness, fatigue, headache, insomnia, mental confusion, paresthesias
-
GI:
diarrhea, epigastric distress, BI bleeding, hepatic toxicity, nausea,
oral thrush, vomiting
-
GU:
menstrual irregularities, proteinuria
-
HEME:
granulocytopenia, leukopenia
-
SKIN:
angioneurotic edema, photosensitivity, rash, urticaria
|
Dosage:
Administered
orally (microsize tablets, ultramicrosize tablets, suspension)
-
Adult:
(microsize) PO 500-1000mg daily in single or divided doses; (ultramicrosize)
330-375mg daily in single or divided doses, max 750mg daily
-
Child:
> or = 2 years: PO (microsize) 10-15 mg/kg/day in single or divided
doses; (ultramicrosize) 5.5-7.3 mg/kg/day in single or divided dose
Duration of Treatment:
Condition |
Duration |
Tinea
corporis |
2-4
weeks |
Tinea
capitis |
at
least 4-6 weeks |
Tinea
pedis |
4-8
weeks |
Tinea
unguium |
3-6
months |
Drug
interactions:
-
Reduces
the response of : Aspirin, Cyclosporine, Oral Contraceptives,
Tacrolimus, and Warfarin
-
Phenobarbital:
reduces plasma griseofulvin level
Special
considerations:
-
Prior
to therapy, the type of fungus responsible for infection should be
identified
-
Response
to therapy may not be apparent for some time; complete entire course
of therapy
-
Avoid
prolonged exposure to sunlight
-
Clinician
should be notified if sore throat or skin rash occurs
-
Store
suspension at room temperature in light-resistant container
|
|
|
|
The information contained here is an
abbreviated summary. For more detailed and complete information, consult the
manufacturer's product information sheets or standard textbooks
Source: Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
This information is provided by The Brookside Associates. The Brookside
Associates, LLC. is a private organization, not affiliated with any governmental
agency. The opinions presented here are those of the author and do not
necessarily represent the opinions of the Brookside Associates or the Department
of Defense. The presence of any advertising on these pages does not constitute
an endorsement of that product or service by either the US Department of Defense
or the Brookside Associates. All material presented here is unclassified.
C. 2009, 2014, All Rights Reserved
|
|